Phase II study of biweekly docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer

Oncology

Volumn 77, Issue 1, 2009, Pages 49-52

  Kakeji, Yoshihiro ^a   Oki, Eiji ^a   Egashira, Akinori ^a   Sadanaga, Noriaki ^a   Takahashi, Ikuo ^a   Morita, Masaru ^a   Emi, Yasunori ^a   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Docetaxel; Gastric cancer; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; DOCETAXEL; ANTINEOPLASTIC AGENT; OXONIC ACID; S 1 (COMBINATION); TAXOID; TEGAFUR;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; DIARRHEA; DRUG EFFICACY; DYSGEUSIA; EPIPHORA; EPISTAXIS; FATIGUE; FEMALE; FEVER; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PIGMENTATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; RECURRENT CANCER; SIDE EFFECT; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; VOMITING; ADENOCARCINOMA; CANCER STAGING; DRUG COMBINATION; FOLLOW UP; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATHOLOGY; PROGNOSIS; STOMACH TUMOR; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADENOCARCINOMA; ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OXONIC ACID; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE; TAXOIDS; TEGAFUR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67649159582     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000226111     Document Type: Article

References (7)

1. Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Takeda S, Unemi N, Fukushima M: Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydrox y-py ridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 1996;56:2602-2606.
2. Boku N, Yamamo to S, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Kimura A, Ohtsu A: Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912). Japan Clinical Oncology Group Trial (abstract). Proc Am Soc Clin Oncol 2007;25:LBA4513.
3. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008;9:215-221.
4. Takahashi I, Emi Y, Kakeji Y, Uchida J, Fukushima M, Maehara Y: Increased antitumor activity in combined treatment TS-1 and docetaxel-a preclinical study using gastric cancer xenografts. Oncology 2005;68:130-137.
5. Takahashi I, Emi Y, Kakeji Y, Tokunaga E, Ushiro S, Oki E, Watanabe M, Baba H, Maehara Y: Phase I study of S-1 and biweekly docetaxel combination chemotherapy for advanced and recurrent gastric cancer. Oncol Rep 20 06;15:849-854.
6. Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y, Todo S, Terashima M, Gotoh M, Sakamoto J, Nishiyama M: Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 2006;12:3402-3407.
7. Yamaguchi K, Shimamura T, Hyodo I, Koizumi W, Doi T, Narahara H, Komatsu Y, Kato T, Saitoh S, Akiya T, Munakata M, Miyata Y, Maeda Y, Ta kiuchi H, Na kano S, Esaki T, Kinjo F, Sakata Y: Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer. Br J Cancer 2006;94:1803-1808.